Ace the PNN 7-Day Live Course 2026 Practice Test – Ignite Your Path to Success!

The recommendation for prophylaxis treatment for Mycobacterium avium complex (MAC) in HIV patients is based on the patient's CD4 cell count and their treatment status. For patients who are not on effective antiretroviral therapy (ART) and have a CD4 count below 50 cells/mm³, prophylaxis is indeed recommended. This is because such individuals are at increased risk of opportunistic infections, including MAC, due to their weakened immune systems.

The use of prophylactic treatment, usually with azithromycin or clarithromycin, helps reduce the incidence of MAC in these vulnerable patients. Regular monitoring of the CD4 count is essential in managing the risk of opportunistic infections effectively; therefore, initiating prophylaxis when a patient is not on HIV treatment and has a low CD4 count is critical to improving their overall health outcomes and quality of life.

While it is true that prophylaxis is specifically indicated when certain criteria are met, the key factor in this scenario is that those not on treatment face a higher risk, thus underlining the importance of being proactive in providing preventive measures.